Yang DH - Search Results

1

Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma.

Pi M, Kuang H, Yue C, Yang Q, Wu A, Li Y, Assaraf YG, Yang DH, Wu S. Pi M, et al. Among authors: yang q, yang dh. Drug Resist Updat. 2022 Mar;61:100822. doi: 10.1016/j.drup.2022.100822. Epub 2022 Mar 4. Drug Resist Updat. 2022. PMID: 35257981 Review.

2

Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer.

Gupta P, Jani KA, Yang DH, Sadoqi M, Squillante E, Chen ZS. Gupta P, et al. Among authors: yang dh. Expert Opin Drug Metab Toxicol. 2016;12(3):281-9. doi: 10.1517/17425255.2016.1145655. Epub 2016 Feb 15. Expert Opin Drug Metab Toxicol. 2016. PMID: 26799671 Review.

3

Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.

Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang DH, Chen ZS. Li W, et al. Among authors: yang dh. Drug Resist Updat. 2016 Jul;27:14-29. doi: 10.1016/j.drup.2016.05.001. Epub 2016 May 13. Drug Resist Updat. 2016. PMID: 27449595 Review.

4

Modulating ROS to overcome multidrug resistance in cancer.

Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, Ashby CR Jr, Yang DH, Chen ZS. Cui Q, et al. Among authors: yang dh. Drug Resist Updat. 2018 Nov;41:1-25. doi: 10.1016/j.drup.2018.11.001. Epub 2018 Nov 14. Drug Resist Updat. 2018. PMID: 30471641 Review.

5

Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma.

Wu S, Kuang H, Ke J, Pi M, Yang DH. Wu S, et al. Among authors: yang dh. Front Oncol. 2021 Jan 15;10:591342. doi: 10.3389/fonc.2020.591342. eCollection 2020. Front Oncol. 2021. PMID: 33520703 Free PMC article. Review.

6

Curcumin reverses doxorubicin resistance in colon cancer cells at the metabolic level.

Zhang N, Gao M, Wang Z, Zhang J, Cui W, Li J, Zhu X, Zhang H, Yang DH, Xu X. Zhang N, et al. Among authors: yang dh. J Pharm Biomed Anal. 2021 Jul 15;201:114129. doi: 10.1016/j.jpba.2021.114129. Epub 2021 May 7. J Pharm Biomed Anal. 2021. PMID: 34000577

7

A novel approach for relapsed/refractory FLT3^mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.

Li KX, Wu HY, Pan WY, Guo MQ, Qiu DZ, He YJ, Li YH, Yang DH, Huang YX. Li KX, et al. Among authors: yang dh. Mol Cancer. 2022 Mar 4;21(1):66. doi: 10.1186/s12943-022-01541-9. Mol Cancer. 2022. PMID: 35246156 Free PMC article.

8

Correction: A novel approach for relapsed/refractory FLT3^mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.

Li KX, Wu HY, Pan WY, Guo MQ, Qiu DZ, He YJ, Li YH, Yang DH, Huang YX. Li KX, et al. Among authors: yang dh. Mol Cancer. 2022 Jun 23;21(1):134. doi: 10.1186/s12943-022-01566-0. Mol Cancer. 2022. PMID: 35739513 Free PMC article. No abstract available.

9

The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond.

Chen DQ, Xie Y, Cao LQ, Fleishman JS, Chen Y, Wu T, Yang DH. Chen DQ, et al. Among authors: yang dh. Drug Resist Updat. 2024 Mar;73:101062. doi: 10.1016/j.drup.2024.101062. Epub 2024 Jan 29. Drug Resist Updat. 2024. PMID: 38330827 Review.

10

bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10).

Chen JJ, Patel A, Sodani K, Xiao ZJ, Tiwari AK, Zhang DM, Li YJ, Yang DH, Ye WC, Chen SD, Chen ZS. Chen JJ, et al. Among authors: yang dh. PLoS One. 2013 Sep 17;8(9):e74573. doi: 10.1371/journal.pone.0074573. eCollection 2013. PLoS One. 2013. PMID: 24069321 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,621 results

Search Page